Precision-Guided Dosing For Inflammatory Bowel Disease Treatment

A recent multicenter retrospective study has demonstrated the transformative potential of precision-guided dosing (PGD) in managing inflammatory bowel disease (IBD), according to an abstract presented at the Advances in Inflammatory Bowel Diseases annual conference in Orlando, Florida.

PGD utilizes pharmacokinetic modeling to optimize infliximab (IFX) dosing based on patient-specific inputs, helping healthcare providers make more precise treatment decisions.

Analyzing data from 82 patients over 24 months, researchers found that PGD-informed adjustments to IFX therapy—ranging from dose reductions to intensifications—led to measurable improvements in disease activity. Patients with forecasted low IFX trough levels (<5 mg/mL) often required intensified or discontinued therapy, while those with high levels (>15 mg/mL) benefited from dose reductions.

The study reported a significant improvement in physician-assessed disease activity 12 months after PGD implementation (mean difference: 0.378; p = 0.008). Economically, PGD resulted in estimated annual savings of $343,796 across the cohort, with reduced hospitalization rates, shorter hospital stays, and fewer office visits contributing to an average cost reduction of $4,193 per patient annually.

“HCPs used PGD to guide treatment decisions. Optimization of IFX therapy led to improved patient outcomes, lower healthcare utilization, and cost savings,” researchers concluded.

Reference:

Arai R, Condino A, Abraham B. Impact of precision-guided dosing on clinical decision making and health care utilization in inflammatory bowel disease: a 24-month real-world outcome comparison before and after test implementation. Presented at: Advances in Inflammatory Bowel Disease annual meeting; December 9-11, 2024. Orlando, Florida.